Mizuki Nishino, MD, MPH of Dana-Farber Cancer Institute gives an overview of her presentation, Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting, which was presented at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 9087: Tumor response dynamics of advanced non-small-cell lung cancer (NSCLC) patients (pts) treated with commercial PD-1 inhibitors in the clinical setting.
Advertisement